Education
About Us
Working with TipRanks
Follow Us
Tango Therapeutics, Inc. (TNGX)
:TNGX
Rmc-6236, Tng462, Rmc-9805
Pancreatic Cancer Metastatic, Lung Cancer, Nsclc, Pdac, Pdac - Pancreatic Ductal Adenocarcinoma, Ras Mutation, Mtap Deletion, Thoracic Cancer
Phase I/II
Recruiting
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Mar 28, 2025
―
Tng462, S095035
Mtap-Deleted Solid Tumors
Phase I/II
Recruiting
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Dec 18, 2023
―
Pembrolizumab, Tng260
Non Small Cell Lung Cancer, Lung Cancer, Solid Tumors, Adult, Lung Adenocarcinoma
Phase I/II
Recruiting
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Apr 18, 2023
―
Pembrolizumab, Tng462
Locally Advanced Solid Tumor
Phase I/II
Recruiting
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Jan 30, 2023
―
Tng908
Locally Advanced Solid Tumor
Phase I/II
Active Not Recruiting
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Feb 18, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Tango Therapeutics, Inc. (TNGX) have in its pipeline
TNGX is currently developing the following drugs: Rmc-6236, Tng462, Rmc-9805, Tng462, S095035, Pembrolizumab, Tng260. These drug candidates are in various stages of clinical development as the company works toward FDA approval.